30-05-2025
B.R.A.I.N. Biotechnology Research and Information Network (0RFI) Receives a Buy from Kepler Capital
In a report released on May 28, Nicolas Pauillac from Kepler Capital maintained a Buy rating on B.R.A.I.N. Biotechnology Research and Information Network (0RFI – Research Report), with a price target of €7.00. The company's shares closed last Tuesday at €2.09.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pauillac covers the Healthcare sector, focusing on stocks such as COSMO Pharmaceuticals N.V., Sandoz Group Ltd, and OSE Immunotherapeutics SA. According to TipRanks, Pauillac has an average return of 11.7% and a 52.00% success rate on recommended stocks.
B.R.A.I.N. Biotechnology Research and Information Network has an analyst consensus of Moderate Buy, with a price target consensus of €8.00.
